denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Bioinformatics, Diseases, Patient-reported outcomes, Real-world evidence, Registries, Lymphoid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Hematology Disease Topics & Pathways:
Research, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Bioinformatics, Diseases, Patient-reported outcomes, Real-world evidence, Registries, Lymphoid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Pacific Ballroom Salons 24-26
(Marriott Marquis San Diego Marina)
Chair:
Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
Disclosures:
No relevant conflicts of interest to declare.
This 90-minute special-interest session will focus on the ASH Research Collaborative’s Multiple Myeloma Program’s efforts to accelerate research and collaborative clinical care in hematologic malignancies. Three topics will describe the ASH Research Collaborative’s approach to aggregating and visualizing real-world data (RWD) in multiple myeloma in a US-based, multi-site network; a proof-of-concept study with a hybrid decentralized workflow that was conducted in the ASH RC Myeloma Network this year; and new directions for RWD analysis in hematologic malignancies, including the use of artificial intelligence. A panel will then highlight work that is being done by the European HARMONY Alliance and other real-world data registries.
See more of: Special-Interest Sessions